Pharming (PHAR) Total Current Liabilities (2019 - 2026)

Pharming's Total Current Liabilities history runs 8 years deep, the most recent figure standing at $112.3 million for Q1 2026.

• Quarterly Total Current Liabilities rose 44.9% year-over-year to $112.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $112.3 million (up 44.9% YoY) and the FY2025 annual result came in at $115.8 million, up 56.89% from the prior year.
• Total Current Liabilities was $112.3 million for Q1 2026 at Pharming, down from $115.8 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $207.3 million in Q1 2024 and bottomed at $46694.0 in Q3 2022.
• A 5-year average of $79.2 million and a median of $77.5 million in 2025 frame the typical range for Total Current Liabilities.
• Annual changes were most pronounced in 2022 — Total Current Liabilities plunged 99.9% — and 2023, when it soared 145653.2%.
• Pharming's Total Current Liabilities stood at $59.7 million in 2022, then surged by 30.6% to $78.0 million in 2023, then slipped by 5.34% to $73.8 million in 2024, then surged by 56.89% to $115.8 million in 2025, then retreated by 2.98% to $112.3 million in 2026.
• Business Quant data shows PHAR's Total Current Liabilities at $112.3 million in Q1 2026, $115.8 million in Q4 2025, and $87.9 million in Q3 2025.